Gland Pharma gets USFDA EIR for Pashamylaram facility

Published On 2023-11-25 06:18 GMT   |   Update On 2023-11-28 12:00 GMT

Hyderabad: Gland Pharma has recently announced that the Company has received an Establishment Inspection Report (EIR) from the US FDA indicating the closure of the inspection at the Company’s Pashamylaram Facility in Hyderabad.

The USFDA inspected the facility between 23rd August, 2023 and 26th August, 2023.

"Further to our intimation dated August 26, 2023; this is to inform you that following the Pre-Market Inspection covering US FDA’s Quality System/Current Good Manufacturing Practice regulations for Medical Devices (21 CFR Part 820) by US FDA at the Company’s Pashamylaram Facility at Hyderabad between 23rd August, 2023 and 26th August, 2023; the Company has received Establishment Inspection Report (EIR) from the US FDA indicating closure of the inspection," Gland Pharma stated in a BSE filing.

Gland Pharma, a generic injectable-focused pharmaceutical company, was established in 1978 in Hyderabad. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions.

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News